Evans, Kaleigh L.
Wirtz, Heidi S.
Li, Jia
She, Ruicong
Maya, Juan
Gui, Hongsheng
Hamer, Andrew
Depre, Christophe
Lanfear, David E.
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (R01HL103871)
Henry Ford Research Foundation (0000000)
Article History
Received: 27 December 2018
Accepted: 22 April 2019
First Online: 21 May 2019
Ethics approval and consent to participate
: The current study was accomplished using data from the Henry Ford Heart Failure Pharmacogenomics Registry. The registry was approved by the local ethics committee (Henry Ford Hospital Institutional Review Board) and registry participants provided written informed consent.
: Our manuscript does not contain any individual person’s data.
: Several of the authors are currently employed by Amgen and a grant from Amgen to Henry Ford Hospital (LANFEAR PI) supported the study. KE, JL, RS, and HG have no disclosures to report. HSW is an employee of Amgen Inc. and reports stock ownership in Amgen Inc. and Teva Pharmaceutical Industries Ltd. AH is an employee and stockholder of Amgen Inc. JM was previously employed by Amgen Inc. during the development of the manuscript. CD is an employee of Amgen Inc. DL serves as a consultant for Amgen Inc., Ortho-McNeill, Abbott, Akros, DCRI, reports ownership in Hridaya, and has received research grants from Amgen Inc., Janssen Pharmaceuticals Inc., Novartis Corporation, and Akros.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.